IFNA2 and neoplasm: Furthermore, low tumor burden is a prerequisite for IFNα anti-tumor response (Eggermont et al. 2012), and we cannot exclude that the mouse and rat models used in this study may have exceeded the tumor burden accessible for beneficial IFNα therapy.